Q3 2025 HLS Therapeutics Inc Earnings Call Transcript

Nov 13, 2025 / 01:30 PM GMT

Release Date Price: C$4.75 (-7.59%)

Transcript

Key Points

Positve

Adjusted EBITDA increased by 19% year-over-year in Q3 and 25% year-to-date, indicating strong profitability growth.
The company has significantly reduced its debt, with a 40% decrease since the end of 2023, strengthening its financial position.
HLS Therapeutics Inc (HLTRF) has successfully defended its market share for Clozaril in Ontario despite increased competition.
The company is preparing for the launch of benpaoic acid in Q2 2026, which is expected to drive future growth.
The US Clozaril business is outperforming expectations, showing resilience and stability.

Negative

Revenue for Q3 was down 4% compared to the previous year, indicating challenges in maintaining sales growth.
Clozaril's Canadian business is projected to decline by 4-5% for the full year due to inventory fluctuations and competitive pressures.
Vascepa's prescription growth is below the company's ambitious targets for the year.
Foreign exchange negatively impacted consolidated revenue by approximately $0.8 million year-to-date.
The company faces headwinds in Canadian product sales, with only a 2% growth year-to-date in local currency.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HLS.TO - HLS Therapeutics Inc
Q3 2025 HLS Therapeutics Inc Earnings Call
Nov 13, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Q3 2025 financial results conference call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations for the introductory remarks. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good morning, everyone, and thank you for joining us today. With me on the call is Craig Million, Chief Executive Officer, John Hannah, Chief Financial Officer, and Brian Walsh, Chief Commercial Officer.

Earlier this morning, we issued a news release announcing our financial results for the 3

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.